This therapeutic concept targets LRRK2 (Leucine-Rich Repeat Kinase 2) kinase hyperactivity with small-molecule inhibitors to slow or prevent Parkinson's disease progression. LRRK2 mutations are the most common genetic cause of familial Parkinson's disease, and pathogenic variants (particularly G2019S) exhibit increased kinase activity that drives α-synuclein phosphorylation, autophagy dysfunction, and dopaminergic neuron vulnerability[@paisnruz2005][@zimprich2004].
Indication: Parkinson's disease (LRRK2-associated and sporadic)
Patient Selection: LRRK2 mutation carriers (G2019S, R1441C/G, I2020T) and sporadic PD with elevated LRRK2 activity
Mechanistic Rationale
The LRRK2 Hyperactivity Problem
Pathogenic LRRK2 mutations cluster in the kinase and GTPase domains, with the most common mutation (G2019S) increasing kinase activity 2-3 fold[@cookson2015]. This hyperactivity drives:
Rab GTPase dysregulation: LRRK2 phosphorylates Rab8A, Rab10, and Rab12 at Thr73, disrupting vesicular trafficking and autophagy-lysosome function[@steger2016]
α-Synuclein phosphorylation: Enhanced Ser129 phosphorylation promotes aggregation and Lewy body formation[@qing2009]
Autophagy impairment: Dysregulated LRRK2 disrupts autophagosome formation and lysosomal function
Mitochondrial dysfunction: Altered mitochondrial dynamics and quality control in dopaminergic neurons
...
Overview
This therapeutic concept targets LRRK2 (Leucine-Rich Repeat Kinase 2) kinase hyperactivity with small-molecule inhibitors to slow or prevent Parkinson's disease progression. LRRK2 mutations are the most common genetic cause of familial Parkinson's disease, and pathogenic variants (particularly G2019S) exhibit increased kinase activity that drives α-synuclein phosphorylation, autophagy dysfunction, and dopaminergic neuron vulnerability[@paisnruz2005][@zimprich2004].
Indication: Parkinson's disease (LRRK2-associated and sporadic)
Patient Selection: LRRK2 mutation carriers (G2019S, R1441C/G, I2020T) and sporadic PD with elevated LRRK2 activity
Mechanistic Rationale
The LRRK2 Hyperactivity Problem
Pathogenic LRRK2 mutations cluster in the kinase and GTPase domains, with the most common mutation (G2019S) increasing kinase activity 2-3 fold[@cookson2015]. This hyperactivity drives:
Rab GTPase dysregulation: LRRK2 phosphorylates Rab8A, Rab10, and Rab12 at Thr73, disrupting vesicular trafficking and autophagy-lysosome function[@steger2016]
α-Synuclein phosphorylation: Enhanced Ser129 phosphorylation promotes aggregation and Lewy body formation[@qing2009]
Autophagy impairment: Dysregulated LRRK2 disrupts autophagosome formation and lysosomal function
Mitochondrial dysfunction: Altered mitochondrial dynamics and quality control in dopaminergic neurons
Why Kinase Inhibition Works
LRRK2 kinase inhibitors work by:
Competing with ATP for binding to the kinase active site
Dopaminergic Neurons — Target cells in substantia nigra
Microglia — Neuroinflammation modulation
Related Treatments
DNL151 — LRRK2 inhibitor in clinical trials
BIIB122 — LRRK2 inhibitor (formerly DNL151)
References
[Paisán-Ruíz C, Jain S, Evans EW, et al, LRRK2 Gene Mutations in Parkinson Disease (2005)](https://doi.org/10.1056/NEJMoa044537)
[Zimprich A, Biskup S, Leitner P, et al, Mutations in LRRK2 Cause Familial Parkinsonism (2004)](https://doi.org/10.1016/j.neuron.2004.11.005)
[Cookson MR, LRRK2 and Parkinson's disease: From the accessorizing to the troublesome (2015)](https://doi.org/10.1002/mds.26097)
[Steger M, Tonelli F, Ito G, et al, Phosphoproteomics Reveals that Parkinson's Disease Kinase LRRK2 Regulates Rab GTPases (2016)](https://doi.org/10.1016/j.cell.2016.09.021)
[Qing H, Wong W, Richardson SL, et al, LRRK2 Phosphorylation of Alpha-Synuclein (2009)](https://pubmed.ncbi.nlm.nih.gov/19445060/)